Actinomycin
Actinomycin D is a polypeptide antibiotic produced from Streptomyces; it exhibits anticancer chemotherapeutic activity but does not display antibacterial benefit. Actinomycin D is clinically used to treat various cancers and is one component of the VAC chemotherapy regimen. Actinomycin D binds DNA, preventing chain elongation and inhibiting RNA polymerase and topoisomerase activity. In cellular and animal models of chronic lymphocytic leukemia (CLL), this compound downregulates expression of Bcl-2 and Mcl-1, induces apoptosis, inhibits cellular proliferation, and decreases tumor burden.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18835813
| Cas No. |
50-76-0 |
|---|---|
| Purity |
≥98% |
| Formula |
C62H86N12O16 |
| Formula Wt. |
1255.50 |
| IUPAC Name |
2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide |
| Synonym |
Actinomycin D; Meractinomycin; Dactinomycin |
| Melting Point |
245-255°C (dec.) |
| Solubility |
Soluble in ethanol, propylene glycol, water + glycol mixture. Soluble in DMSO (50mg/mL) and methanol (10mg/mL). |
| Appearance |
Salmon Pink Crystal Powder |
Merkel O, Wacht N, Sifft E, et al. Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia. Leukemia. 2012 Dec;26(12):2508-16. PMID: 22743622.
Koba M, Konopa J. Actinomycin D and its mechanisms of action. Postepy Hig Med Dosw (Online). 2005;59:290-8. PMID: 15995596.
Sobell HM. Actinomycin and DNA transcription. Proc Natl Acad Sci U S A. 1985 Aug;82(16):5328-31. PMID: 2410919.
